Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Accured Expenses (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Change in Accured Expenses for 6 consecutive years, with -$573000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 78.52% year-over-year to -$573000.0, compared with a TTM value of -$1.4 million through Sep 2025, up 71.57%, and an annual FY2024 reading of $456000.0, down 77.12% over the prior year.
  • Change in Accured Expenses was -$573000.0 for Q3 2025 at Barinthus Biotherapeutics, down from -$245000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.6 million in Q3 2022 and bottomed at -$4.3 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is $225105.3, with a median of -$108000.0 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 2720.37% in 2022, while the deepest fall reached 479.63% in 2022.
  • Year by year, Change in Accured Expenses stood at $2.6 million in 2021, then crashed by 267.83% to -$4.3 million in 2022, then grew by 24.89% to -$3.2 million in 2023, then skyrocketed by 161.22% to $2.0 million in 2024, then plummeted by 128.88% to -$573000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for BRNS at -$573000.0 in Q3 2025, -$245000.0 in Q2 2025, and -$2.5 million in Q1 2025.